Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 50mg | $29.99 | $0.60/mg | In stock | Jul 4 |
| vial | 20mg | $56.99 | $2.85/mg | In stock | Jul 4 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| KC-GHK-02 | Mar 2026 | — | Freedom Diagnostics | — | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHK-Cu is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Kimera Chems sell GHK-Cu?
Yes — Kimera Chems currently lists GHK-Cu in 2 variants starting at $29.99 ($0.60/mg).
Is Kimera Chems's GHK-Cu third-party tested?
Yes — Disclosed Labs has indexed 8 Certificates of Analysis for Kimera Chems's GHK-Cu, with the most recent showing 99.2% purity. Kimera Chems holds an overall trust grade of C (70/100) across all 355 COAs on file.
What is Kimera Chems's trust grade for GHK-Cu?
Kimera Chems has an overall Disclosed Labs trust grade of C (70/100), computed from 355 COAs across all peptides. The most recent GHK-Cu COA was issued by Freedom Diagnostics.
Where is the cheapest GHK-Cu?
As of the latest data, Sunrise Bioresearch offers GHK-Cu at $0.09/mg — compare with Kimera Chems's listing at $0.60/mg. See the full GHK-Cu price comparison.
Is GHK-Cu legal to buy?
GHK-Cu is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| KC-GHK-CLR1 | Feb 2026 | 99.2% | Freedom Diagnostics | — | Confirmed | View |
| A-GHK-001 | Jan 2026 | — | Vanguard Laboratory | Sterility | Unverified | View |
| KC-GHK-WHT1 | Jan 2026 | 99.8% | Vanguard Laboratory | Sterility | Confirmed | View |
| KC-GHK-01 | Sep 2025 | 100.0% | Freedom Diagnostics | — | Unverified | View |
| Copper Crimp | — | 99.3% | Vanguard Laboratory | — | Unverified | View |
| KC-GHK-BLK1 | — | 99.8% | Vanguard Laboratory | Endotoxin, Sterility, Heavy metals | Confirmed | View |
| Red Cap | — | 99.8% | Vanguard Laboratory | — | Unverified | View |